Natera, Inc. $NTRA Shares Sold by Hsbc Holdings PLC

Posted by Stanley Muller on Jun 25th, 2026

Hsbc Holdings PLC decreased its position in Natera, Inc. (NASDAQ:NTRA – Free Report) by 33.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 105,005 shares of the medical research company’s stock after selling 52,264 shares during the period. Hsbc Holdings PLC’s holdings in Natera were worth $24,170,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the company. Horizon Investments LLC raised its holdings in Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after purchasing an additional 44 shares in the last quarter. Sound Income Strategies LLC boosted its holdings in Natera by 20.0% in the 4th quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company’s stock valued at $62,000 after purchasing an additional 45 shares in the last quarter. Savvy Advisors Inc. boosted its holdings in Natera by 3.1% in the 4th quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company’s stock valued at $353,000 after purchasing an additional 46 shares in the last quarter. Siemens Fonds Invest GmbH increased its position in Natera by 3.1% during the 3rd quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after purchasing an additional 54 shares during the period. Finally, Alamea Verwaltungs GmbH increased its position in Natera by 2.9% during the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock worth $515,000 after purchasing an additional 62 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera News Roundup

Here are the key news stories impacting Natera this week:

Positive Sentiment: Japan approved Signatera for colorectal cancer, making it the first PMDA-approved MRD test in the country and opening a new international market for Natera. Why Natera (NTRA) Is Up 6.7% After Japan Approves First MRD Test for Colorectal Cancer
Positive Sentiment: Signatera also received regulatory approval in Japan for colorectal cancer, reinforcing the significance of the launch and the potential for broader commercial traction. Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer
Positive Sentiment: Japan’s approval for Signatera has been described as a landmark win, highlighting Natera’s leadership in MRD testing and likely boosting investor confidence in the platform. Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer
Positive Sentiment: The NCCN updated bladder cancer guidelines to recommend ctDNA-MRD testing using Signatera technology, which may further validate the product and support more testing volume. NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
Neutral Sentiment: Natera announced a partnership with Pirche to connect transplant risk assessment with Prospera monitoring, a strategic collaboration that could broaden its transplant diagnostics workflow but is less immediately material than the Signatera news. Natera (NTRA) Teams With Pirche To Link Transplant Risk And Prospera Monitoring
Neutral Sentiment: Barclays trimmed its price target to $260 while keeping an overweight rating, which may have capped some enthusiasm but does not change the overall bullish tone. Benzinga analyst update
Neutral Sentiment: BTIG raised its price target to $270 and reiterated a buy rating, adding another supportive analyst signal for the stock. Benzinga analyst update

Analyst Upgrades and Downgrades

Several analysts have recently commented on NTRA shares. Morgan Stanley reduced their price target on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Wolfe Research initiated coverage on Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective on the stock. Robert W. Baird set a $265.00 price objective on Natera in a research report on Friday, May 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. Finally, JPMorgan Chase & Co. boosted their target price on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average target price of $256.24.

View Our Latest Report on NTRA

Insider Buying and Selling

In related news, Director Rowan E. Chapman sold 2,964 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total value of $642,535.92. Following the sale, the director directly owned 3,124 shares in the company, valued at $677,220.72. The trade was a 48.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the sale, the director directly owned 6,183 shares in the company, valued at approximately $1,343,009.43. The trade was a 64.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 162,342 shares of company stock valued at $35,283,396 in the last three months. 5.05% of the stock is owned by insiders.

Natera Price Performance

NTRA opened at $259.97 on Thursday. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $264.65. The stock has a market cap of $37.23 billion, a P/E ratio of -159.49 and a beta of 1.56. The stock’s 50 day simple moving average is $210.71 and its 200 day simple moving average is $215.43.

Natera Company Profile

(Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.